SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired Fate securities during the Class Period, you have until March 22, 2023 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Fate is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders.

On April 2, 2020, after the market closed, Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the “Janssen Collaboration Agreement”). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. On the news, Fate’s stock price jumped 8.8% in trading on April 3, 2020.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On January 5, 2023, after the markets closed, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement. Specifically, the Company disclosed that it was “not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023[.]” As a result of the termination, Fate revealed that all licenses and other rights granted pursuant to the Janssen Collaboration Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers, including FT516 and FT538 NK cell programs in acute myeloid leukemia, FT516 and FT596 NK cell programs in B-cell lymphoma, and FT538 and FT536 NK cell programs in solid tumors.

On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980



SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

TIN LIÊN QUAN

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

CRBU Class Action Lawsuit Announced: Johnson Fistel

SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...

BROS EQUITY ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM,

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atlassian

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atlassian...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kornit Digital

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kornit...

SUNL FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL,

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sunlight...

THỦ THUẬT HAY

Cách tắt nguồn iPhone

Bạn mới sử dụng iPhone và không biết cách tắt nguồn cho iPhone của mình, bài viết dưới đây sẽ hướng dẫn cho bạn một số cách để có thể tắt nguồn nhanh chóng cho iPhone.

Hướng dẫn thay đổi âm thông báo trên điện thoại Android

Nhiều người dùng khi mua một chiếc điện thoại về và để nhạc chuông mặc định theo máy trong một khoảng thời gian khá dài. Điều này về lâu về dài sẽ gây ra nhàm chán cho người sử dụng.

Cách phát video YouTube khi tắt màn hình trên iPhone

Khi xem video Youtube trên iPhone, nếu tắt màn hình thì video cũng ngừng phát và người dùng không thể xem video được nữa. Tuy nhiên, một số ứng dụng sẽ giúp bạn có thể xem video Yotube khi tắt màn hình iPhone.

Hướng dẫn cài đặt "PPSSPP", trình giả lập máy PSP trên iPhone, iPad không cần Jailbreak

PPSSPP là một trình giả lập chuyên dùng để chơi các tựa game của máy PSP (loại máy chơi game cosole cầm tay của sony) trên Smartphone và PC.

Cách cập nhật iOS 15.2 Beta 3, giúp bạn hạn chế bị theo dõi địa chỉ IP

Apple hôm nay đã phát hành iOS 15.2 Beta 3 với sự cải tiến chế độ Macro, tinh chỉnh iCloud Private Relay và hơn thế nữa. Sau đây là cách cập nhật iOS 15.2 Beta 3...

ĐÁNH GIÁ NHANH

So sánh iPhone 13 và iPhone 11: Phiên bản mới có xứng đáng để nâng cấp?

Mới đây, Apple đã trình làng dòng điện thoại iPhone 13 mới với nhiều nâng cấp, cải tiến. Dù đây là một sản phẩm hấp dẫn tuy nhiên sẽ có nhiều người dùng iPhone 11 băn khoăn liệu có lên đời iPhone 13 không? Câu trả lời

Đánh giá giao diện người dùng trên Asus ZenFone 3: Đa tính năng, nhiều tùy biến

Giao diện người dùng trên Asus ZenFone 3 khá nhẹ nhàng, đa tính năng và nhiều tùy biến.

So sánh cấu hình, hiệu năng Snapdragon 625 và Exynos 7872: Lựa chọn nào tốt hơn?

Mới đây, Samsung vừa chính thức ra mắt bộ vi xử lý mới thuộc phân khúc tầm trung của hãng là Exynos 7872 và nó đã được trang bị trên chiếc smartphone vừa mới ra mắt của Meizu là M6s.